



CS/NSE&BSE/UFR/2017-18
January 30, 2018

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Stock Code: SUVEN–EQ

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001
Stock Code: 530239

Dear Sir/Madam,

Sub: Notification of Un-audited Financial Results for the quarter and nine months ended 31st December, 2017

.....


With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 30th January, 2018, has taken on record the Standalone Un-audited Financial Results of the Company under Ind AS for the quarter and nine months ended 31st December, 2017 and approved the following matters.

- (1) The Board declared an interim dividend of Rs. 1.50 per equity share of face value Rs 1/- each for the year 2017-2018.
- (2) The Board approved the **Record Date i.e., 07th February 2018** notified by the Company for the purpose of payment of interim dividend to the eligible shareholders.
- (3) The above said dividend will be paid on and from **15th February, 2018**.

We are enclosing herewith the **Un-audited Financial Results** under Ind AS **for the quarter and nine months ended 31st December, 2017** along with **Limited Review Report of Statutory Auditors of the Company**.

Please find enclosed **Press Release** of our company. We request you to take these documents on your records. The Board Meeting concluded at 12:25 P.M.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**


K Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7
Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com



SUVEN LIFE SCIENCES LIMITED

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suvan.com website: www.suvan.com

STATEMENT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER 2017

All amounts in Indian Rupees in lakhs

Sl. No.	Particulars	For the Quarter ended			For the Nine Months ended		For the Year Ended
		31-Dec-2017	30-Sep-2017	31-Dec-2016	31-Dec-2017	31-Dec-2016	31-Mar-2017
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Revenue from operations						
	(a) Net sales/income from operations (Refer Note 3)	16,273.88	10,409.95	11,539.43	40,428.73	36,417.10	53,916.74
	(b) Other operating income	91.85	275.93	15.89	724.78	15.89	531.04
	Total Revenue from operations	16,365.73	10,685.88	11,555.32	41,153.51	36,432.99	54,447.78
2	Other Income	328.95	513.23	490.15	1,404.47	1,615.40	2,109.25
	Total Income (1+2)	16,694.68	11,199.11	12,045.47	42,557.98	38,048.39	56,557.03
3	Expenses						
	(a) Cost of materials consumed	5,104.86	4,218.13	3,852.71	13,006.52	11,245.30	15,480.66
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(185.72)	(3,189.36)	(1,607.90)	(3,602.25)	(2,530.55)	(295.94)
	(d) Employee benefits expense	1,481.60	1,267.76	1,262.91	4,315.58	3,610.93	5,064.46
	(e) Finance costs	115.16	93.58	126.47	335.75	409.76	566.58
	(f) Depreciation and amortisation expenses	541.66	533.99	487.20	1,594.85	1,423.00	2,141.31
	(g) Manufacturing expenses	2,379.39	2,101.03	1,975.74	6,670.79	5,625.94	8,157.37
	(h) Research & Development expenses	1,387.83	1,166.13	1,635.97	4,155.15	4,570.34	6,494.09
	(i) Other expenses	1,058.62	622.66	749.64	2,440.34	2,193.32	3,012.81
	Total expenses	11,883.40	6,813.92	8,482.74	28,916.73	26,548.04	40,621.34
4	Profit before exceptional items and tax (1+2-3)	4,811.28	4,385.19	3,562.73	13,641.25	11,500.35	15,935.69
5	Exceptional Items	-	-	-	-	-	-
6	Profit before tax (4 - 5)	4,811.28	4,385.19	3,562.73	13,641.25	11,500.35	15,935.69
7	Tax Expenses						
	(a) Current tax	1,014.68	592.11	949.47	2,739.56	3,131.60	3,275.07
	(b) Deferred tax	336.78	618.35	186.19	1,310.07	28.35	313.25
8	Net Profit for the period / year (6-7)	3,459.82	3,174.73	2,427.07	9,591.62	8,340.40	12,347.37
9	Other Comprehensive Income						
9.A	(i) Items that will not be reclassified to profit or loss	(3.73)	(3.72)	(11.31)	(11.18)	(33.92)	(14.90)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	1.29	1.29	-	3.87	-	5.15
9.B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income	(2.44)	(2.43)	(11.31)	(7.31)	(33.92)	(9.75)
	Total Comprehensive Income (8+9)	3,457.38	3,172.30	2,415.76	9,584.31	8,306.48	12,337.62
10	Paid-up equity share capital (face value of Rs. 1/- each)	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
11	Earning Per Share (EPS) for continuing operation (face value of Rs.1/- each):						
	a) Basic	2.72	2.49	1.90	7.53	6.53	9.69
	b) Diluted	2.72	2.49	1.90	7.53	6.53	9.69


See accompanying notes to the financial statements

SEGMENT WISE REVENUE, RESULTS TOTAL ASSETS AND LIABILITIES

PARTICULARS	For the Quarter Ended			For the Nine Months ended		For the Year Ended
	31-Dec-2017	30-Sep-2017	31-Dec-2016	31-Dec-2017	31-Dec-2016	31-Mar-2017
	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1 SEGMENT REVENUE						
a) Manufacturing (CRAMS)	15,693.88	10,026.47	10,682.46	39,051.11	34,169.91	51,670.07
b) Services (DDDSS)	671.85	659.41	856.99	2,102.40	2,263.08	2,777.71
c) Research & Development	-	-	-	-	-	-
Total	16,365.73	10,685.88	11,539.45	41,153.51	36,432.99	54,447.78
Less: Inter Segment Revenue	-	-	-	-	-	-
Net Sales/Income from Operations	16,365.73	10,685.88	11,539.45	41,153.51	36,432.99	54,447.78
2 SEGMENT RESULTS (Profit/(Loss) before tax and interest)						
a) Manufacturing (CRAMS)	6,444.25	5,312.13	4,999.12	17,539.24	15,292.47	21,634.85
b) Services (DDDSS)	267.76	319.36	439.15	992.37	1,201.13	1,476.81
c) Research & Development	(1,387.83)	(1,166.14)	(1,635.97)	(4,155.15)	(4,570.34)	(6,494.09)
TOTAL	5,324.18	4,465.35	3,802.30	14,376.46	11,923.26	16,617.57
Less: i) Finance Cost	72.41	74.19	93.12	233.71	301.37	376.38
ii) Other Un-allocable expenditure /(income), net	440.49	5.97	146.45	501.50	121.54	305.50
Total Profit Before Tax	4,811.28	4,385.19	3,562.73	13,641.25	11,500.35	15,935.69
3 SEGMENT ASSETS :						
a) Manufacturing (CRAMS)	56,835.94	53,711.58	51,397.78	56,835.94	51,397.78	43,886.93
b) Services (DDDSS)	4,174.47	4,077.86	2,693.72	4,174.47	2,693.72	2,828.60
c) Research & Development	3,117.69	2,896.37	2,489.66	3,117.69	2,489.66	2,609.60
d) Un allocated	35,007.49	35,647.25	29,713.48	35,007.49	29,713.48	38,291.82
TOTAL	99,135.59	96,333.06	86,294.64	99,135.59	86,294.64	87,616.95
4 SEGMENT LIABILITIES :						
a) Manufacturing (CRAMS)	9,663.85	9,984.93	8,727.74	9,663.85	8,727.74	8,547.86
b) Services (DDDSS)	498.66	574.83	491.00	498.66	491.00	370.23
c) Research & Development	1,866.63	2,253.38	2,113.04	1,866.63	2,113.04	1,848.18
d) Un allocated	856.23	925.45	803.03	856.23	803.03	687.23
TOTAL	12,885.37	13,738.59	12,134.81	12,885.37	12,134.81	11,453.50

- Notes:**
- The Company has adopted Indian Accounting Standards ("Ind AS") from April 1 2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.
 - The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 30th January, 2018 and the same reviewed by the Statutory Auditors.
 - Excise duty on sales was included under Revenue from operations and disclosed separately under expenses up to all reporting periods ending 30-June-2017. Post implementation of Goods and Service Tax (GST) Act w.e.f. 1st July, 2017 the revenue from operations is reported for the period ended 31-Dec-2017 is net of GST and hence to that extent not comparable.
 - The corresponding previous period figures have been regrouped / reclassified where ever necessary.
 - The Board has declared an Interim Dividend of Rs. 1.50 per equity share of face value of Rs. 1.00 each for the financial year 2017-18, The outflow on account of Interim dividend including dividend distribution tax is Rs. 2297.91 lakhs.

For SUVEN LIFE SCIENCES LTD



Place: Hyderabad
Date: 30th January, 2018

VENKAT JASTI
Chairman & CEO
DIN: 00278028

We Deliver



Ref No.LR/04/2017-18:

LIMITED REVIEW REPORT

To

The Board of Directors of
SUVEN LIFE SCIENCES LIMITED

We have reviewed the accompanying statement of Unaudited Financial Results ("The Statement") of **SUVEN LIFE SCIENCES LIMITED**, ("the Company") having registered office at SDE Serene Chambers, 6th Floor, Avenue 7, Road No. 5, Banjara Hills, Hyderabad - 500034, Telangana, for the quarter and nine months ended 31st December, 2017 attached here with, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Regulations,2015") read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05, July 2016.

The Preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, Interim Financial reporting (IND AS 34) prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05 July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company meeting held on 30th January 2018. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement ("SRE") 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India ("ICAI"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Comparative financial results of the Company for the quarter and nine months ended 31st December 2016 and for the year ended 31 March 2017 ("together referred to as the comparative financial results"), prepared in accordance with Indian Accounting Standards ("IND AS") included in these financial results have been reviewed/audited by the predecessor auditor who had reviewed/audited the financial results for the relevant period and expressed an unmodified opinion as per the reports dated 1st February 2017 and 13 May 2017 respectively.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable Ind AS prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of SEBI Regulations 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **TUKARAM & CO.**,
Chartered Accountants
(Firm Registration No.0044365)

(RAJENDER REDDY K)
PARTNER
M.No. 231834



Place: Hyderabad
Date: 30/01/2018

News Release

Suven Revenue up by 11.85%; PAT up by 15.38% for 9 months ended December' 2017

HYDERABAD, INDIA (30 January' 2018) – Suven Life Sciences Limited, a biopharmaceutical company specialized in CRAMS for global life science companies and drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 31st December 2017. The Un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 30th Jan' 2018 at Hyderabad.

Financial Highlights for the 3rd Quarter ended December' 2017 (QoQ):

Growth in income	INR 1669 Mn vs 1120 Mn - up by 49.07%
Growth in PAT	INR 346 Mn vs 317 Mn - up by 8.99%
Growth in EBIDTA	INR 547 Mn vs 501 Mn - up by 9.08%

Financial Highlights for the 9 months' period ended December' 2017 (YoY):

Growth in income	INR 4256 Mn vs 3805 Mn - up by 11.85%
Growth in PAT	INR 958 Mn vs. 831 Mn - up by 15.38%
Growth in EBIDTA	INR 1557 Mn vs 1333 Mn - up by 16.79%

Suven's expenses on innovative R&D in Drug Discovery stood at INR 416 Mn (9.76% on revenue) for the 9 months' period ended Dec' 2017.

The Board has declared an Interim Dividend of Re. 1.50 per share (150% of face value of Rs. 1.00 each).

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Suven Life Sciences Limited